Other Talks in the Category: Pharmaceutical Sciences

Hi, my name is Yaning Wang. I'll present the pharmacometrics in pain management on behalf of the author list.
First of all, I would like to point out that opinions expressed in this presentation are those of the authors and may not necessarily be consistent with some of the current product development standards of the regulatory agencies. To obtain the most current standards or advice for drug development, for opioids or any products being developed, the readers should contact the regulatory agency.
In this talk, I will start with the background about pain and pain management, followed by a general introduction of the modeling in chronic and acute pain. Then I will talk about the application of pharmacometrics in clinical patient care and opioid treatments. Then I will use two case studies to demonstrate how pharmacometrics can be applied in the regulatory decision making process. And finally, I will finish with a summary.
Pain is a dynamic phenomenon. It is defined by the International Association for the Study of Pain as unpleasant sensory and emotional experience associated with actual or potential tissue damage or is described in terms of such damage. The sensation results from nerve impulses reaching the cerebral cortex via specific neural pathways and is modulated at all levels of peripheral and central nervous systems. The prevalence of chronic pain is high in industrialized countries. It has been estimated that about 100 million adults suffer from chronic pain in the United States alone, with treatment costs and loss of productivity added up to 635 billion per year. Globally, about 20% of adults suffer from pain and 10% of adults become new chronic pain patients each year. Life quality of a patient with chronic pain is largely compromised because of the persistent nature of the symptom.